bm-42304 and Diabetes-Mellitus--Type-2

bm-42304 has been researched along with Diabetes-Mellitus--Type-2* in 1 studies

Trials

1 trial(s) available for bm-42304 and Diabetes-Mellitus--Type-2

Article	Year
[Results of clinical trials with the gluconeogenesis inhibitor 2-(3-methylcinnamylhydrazono)-propionate (MCHP)]. Klinische Wochenschrift, 1989, Apr-17, Volume: 67, Issue:8 Many compounds which directly or indirectly inhibit gluconeogenesis have been described. Some of them showed hypoglycemic action in animal experiments. 2-(3-Methylcinnamylhydrazono)-Propionat (MCHP) a derivative of hydrazine demonstrated marked hypoglycemic action in animal experiments. Nontheless the administration of MCHP to type II diabetic patients showed no hypoglycemic action. Clinical or biochemical sideeffects could not be observed. Topics: Aged; Aged, 80 and over; Blood Glucose; Cinnamates; Diabetes Mellitus, Type 2; Drug Evaluation; Female; Gluconeogenesis; Glyburide; Humans; Hypoglycemic Agents; Male; Random Allocation	1989

Article

Year

[Results of clinical trials with the gluconeogenesis inhibitor 2-(3-methylcinnamylhydrazono)-propionate (MCHP)].

Klinische Wochenschrift, 1989, Apr-17, Volume: 67, Issue:8

Many compounds which directly or indirectly inhibit gluconeogenesis have been described. Some of them showed hypoglycemic action in animal experiments. 2-(3-Methylcinnamylhydrazono)-Propionat (MCHP) a derivative of hydrazine demonstrated marked hypoglycemic action in animal experiments. Nontheless the administration of MCHP to type II diabetic patients showed no hypoglycemic action. Clinical or biochemical sideeffects could not be observed.

Topics: Aged; Aged, 80 and over; Blood Glucose; Cinnamates; Diabetes Mellitus, Type 2; Drug Evaluation; Female; Gluconeogenesis; Glyburide; Humans; Hypoglycemic Agents; Male; Random Allocation

1989